Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 6/20 | 0.37 |
| ▸ | ATR | Q13535 | 4/20 | 0.37 |
| ▸ | ATRIP | Q8WXE1 | 4/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572685 | 0.85 | MEN1 (0.46) | PRKDC | |
| SCHEMBL5604298 | 0.85 | PRKDC (0.42) | HTR6PRKDC | |
| SCHEMBL4965302 | 0.85 | MAPK7 (0.43) | PRKDCALDH1A1 | |
| SCHEMBL5604831 | 0.84 | PRKDC (0.50) | PRKDC | |
| SCHEMBL5604488 | 0.84 | PRKDC (0.47) | PRKDC | |
| SCHEMBL3566238 | 0.83 | ACVR1 (0.45) | PRKDCALDH1A1ALK | |
| SCHEMBL3557702 | 0.83 | FGFR2 (0.44) | PRKDCALDH1A1 | |
| SCHEMBL27739405 | 0.82 | ADRB2 (0.44) | PRKDC | |
| SCHEMBL3558524 | 0.82 | NTRK1 (0.43) | PRKDC | |
| SCHEMBL4966092 | 0.82 | KHK (0.41) | PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| CN-101243065-A | Intermediates for the synthesis of alkylquinoline and alkylquinazoline kinase modulators and related synthetic methods | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1891040-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| WO-2006135646-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | FLT3, ABL1, KIT | HTR6 497/4885PDE7A 2816/4885PRKDC 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.